GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Atyr Pharma Inc (LIFE) [hlAlert]

Rating:
Buy LIFE
down 55.47 %

Lifeline Systems (LIFE) rated Buy with price target $36 by Wall Street Access

Posted on: Friday,  Feb 13, 2009  10:25 AM ET by Wall Street Access

Wall Street Access rated Buy Atyr Pharma Inc (NASDAQ: LIFE) on 02/13/2009, when the stock price was $30.84.
Since then, Atyr Pharma Inc has lost 55.48% as of 12/16/2015's recent price of $13.73.
If you would have followed this Wall Street Access's recommendation on LIFE, you would have lost 55.47% of your investment in 2497 days.

Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology placing Invitrogen's products in nearly every major laboratory in the world.

We stay on top of the markets that you're interested in, watch for news and opportunities, and keep you informed of any trends or moves in the market that may affect your situation. We have many relationships which give us the ability to make our customers aware of potential opportunities and threats in the market. Our brokers have a depth of understanding rare in the brokerage industry, and an ability to handle your trades with finesse.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/29/2009 11:25 AM Buy
None
36.85 40.00
as of 12/31/2009
1 Week up  3.46 %
1 Month up  8.43 %
3 Months up  15.96 %
1 YTD up  46.48 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/13/2009 10:25 AM Buy
None
30.84 36.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy